As one of the biggest pharmaceutical companies in the world, Merck (NYSE:MRK) is constantly battling generic drugmakers in court. Take a look at some of its recent annual or quarterly SEC filings and you're sure to see huge sections devoted to its patent litigation struggles against a number of companies.

Recently, Merck was able to protect its cholesterol drugs Zetia and Vytorin from earlier-than-expected competition from Mylan (NASDAQ:MYL). In this video, health care analyst Max Macaluso discusses what happened and how these drugs fit into Merck's overall business.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.